Condition
Non-small Lung Cancer
Total Trials
5
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Terminated2
Not Yet Recruiting1
Recruiting1
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07308106Phase 2RecruitingPrimary
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
NCT06293690Phase 2Active Not RecruitingPrimary
Toripalimab Combined With SBRT for NSCLC
NCT07199010Not Yet RecruitingPrimary
Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
NCT02491775Terminated
Afatinib Genomic Landscape
NCT02554591Terminated
Genomic Landscape of Ceritinib
Showing all 5 trials